-
Mashup Score: 1IASLC Launches Global Member Survey on Diversity, Equity, and Inclusion - ILCN.org (ILCN/WCLC) - 10 day(s) ago
The association seeks input from members to better understand the current DEI landscape so it can continue to build a diverse international community dedicated to the elimination of thoracic malignancies.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5US Food and Drug Administration Accepts New Drug Application for Ensartinib - ILCN.org (ILCN/WCLC) - 11 day(s) ago
The filing was based on results from a global phase III study designed to compare the ALK inhibitor to crizotinib in the first-line treatment of ALK-positive NSCLC.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology - ILCN.org (ILCN/WCLC) - 12 day(s) ago
Profs. Jan von der Thüsen and John Le Quesne say while still in the early phases, AI has the potential to bring accessible and affordable prognosis and response prediction tools to all.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm - ILCN.org (ILCN/WCLC) - 17 day(s) ago
During the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR - ILCN.org (ILCN/WCLC) - 24 day(s) ago
The move was supported by preliminary evidence from a phase I, first-in-human study in patients with advanced NSCLC.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19Should Biomarkers Be Used in the Clinical Management of ES-SCLC? - ILCN.org (ILCN/WCLC) - 25 day(s) ago
During a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC - ILCN.org (ILCN/WCLC) - 26 day(s) ago
In light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Regulating Artificial Intelligence - ILCN.org (ILCN/WCLC) - 27 day(s) ago
The US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
The IASLC is seeking member feedback to better support its diverse international community. Read more in #ILCN: https://t.co/A7CgSoqrFe #LCSM